West Pharmaceutical Services, Inc. Appoints Robert Friel as Newest Member to the Board of Directors
February 17, 2020 at 11:00 am
Share
West Pharmaceutical Services Inc. announced the Company's Board of Directors has elected Robert Friel as its newest member. With the addition of Mr. Friel, West's Board of Directors increases in size to 11 directors. Mr. Friel recently retired as Chairman and Chief Executive Officer of PerkinElmer Inc., a role he served in for more than 10 years. During his 20-year career at PerkinElmer, a global business dedicated to serving the diagnostics, life sciences, food and applied markets, Mr. Friel held roles of increasing responsibility that included Chief Operating Officer, President of the Life and Analytical Sciences Division and Chief Financial Officer. Prior to joining PerkinElmer, Mr. Friel served in several finance-focused senior management positions with AlliedSignal Inc., now Honeywell International. Mr. Friel sits on the Board of Directors of New York Life Insurance Company, NuVasive Inc. and Xylem Inc. He has prior board experience with CareFusion Inc., Fairchild Semiconductor Inc. and Millennium Pharmaceuticals Inc.Mr. Friel holds a Master of Science degree in taxation from Fairleigh Dickinson University and a Bachelor of Arts degree in economics from Lafayette College.
West Pharmaceutical Services, Inc. specializes in the design, manufacture and marketing of components and systems for the containment and delivery of injectable drugs. The group offers packaging, components for syringes, cartridge systems, auto-injection devices, accessories for vials, specialty components, etc. Net sales break down by family of products as follows:
- own manufactured products (81.8%);
- products manufactured under contract (18.2%).
Net sales are distributed geographically as follows: the United States (42.3%), Germany (16.8%), Ireland (8.7%), France (7.5%), Europe (12.1%) and other (12.6%).
WEST PHARMACEUTICAL SERVICES, INC. 
